biostudies-literatureUnknown112(2)Paine H<h4>Background</h4>Long-term symptom burden and health-related quality-of-life outcomes after curative oesophageal cancer treatment are poorly understood. Existing tools are cumbersome and do not address the post-treatment population specifically. The aim of this study was to validate the six-symptom LASORS tool for identifying patients after curative oesophageal cancer treatment with poor health-related quality of life and to assess its clinical utility.<h4>Methods</h4>Between 2015 and 2019, patients from 15 UK centres who underwent curative-intent oesophageal cancer treatment, and were disease-free at least 1 year after surgery, were invited to participate in the study and complete LASORS and European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OG25 questionnaires. The British journal of surgeryznae319https://www.ebi.ac.uk/biostudies/studies/S-EPMC11843645biostudies-literatureLAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study.PMC11843645Vohra RSAbbassi-Ghadi NMaynard NBehrens PMohammadi BQureshi YPaine HAwad SJohar APreston SRGriffiths EAUnderwood TMarkar SRGossage JDai NHanna GBLagergren PO'Neill JRAlkhaffaf BChidambaram SSingh PJones RDawas KfalseLAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study.<h4>Background</h4>Long-term symptom burden and health-related quality-of-life outcomes after curative oesophageal cancer treatment are poorly understood. Existing tools are cumbersome and do not address the post-treatment population specifically. The aim of this study was to validate the six-symptom LASORS tool for identifying patients after curative oesophageal cancer treatment with poor health-related quality of life and to assess its clinical utility.<h4>Methods</h4>Between 2015 and 2019, patients from 15 UK centres who underwent curative-intent oesophageal cancer treatment, and were disease-free at least 1 year after surgery, were invited to participate in the study and complete LASORS and European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OG25 questionnaires. 2025-01-01T00:00:00Z2025 Feb2025-07-03T03:04:34.945Z2025-04-03T23:56:44.813ZS-EPMC118436453998237810.1093/bjs/znae319